Psychotic Disorders Clinical Trial
Official title:
Cognitive Behavioural Therapy- Social Functioning In Adolescence With Recent Onset Schizophrenia
Rationale: There is growing consensus that targeting negative symptoms such as social
withdrawal is essential to be able to preserve social participation, thereby reducing the
high yearly costs of schizophrenia. Aaron T. Beck, founder of Cognitive Behavioural Therapy
(CBT), and colleagues have developed and investigated a new CBT approach, in which they
target inactivity in a chronic schizophrenia population with severe negative symptoms The
therapy is based on accumulating evidence that dysfunctional beliefs in conjunction with
neurocognitive impairments can impede social functioning. These results suggest that CBT can
be highly successful in establishing clinically meaningful improvements. However, the therapy
has not yet been investigated in a recent-onset population.
Objective: To evaluate the applicability and (cost-) effectiveness of a shortened, partly
group based, Cognitive Behavioural Therapy focussing on social activation (CBTsa) in patients
with recent onset schizophrenia.
Hypotheses: 1) the investigators hypothesized that CBT focused on social activation (CBTsa)
in a recent-onset population will result in a substantial reduction in severity of negative
symptoms, in particular social withdrawal.
2) The investigators expected that CBTsa would lead to an improvement in terms of Quality of
Life and overall functioning.
3) The investigators expected this intervention to result in a reduction in need for care and
QALY gain as a consequence of improvement in symptoms and social functioning.
Study design: Single blind randomized controlled trial with 6 month-follow up. Study
population: Patients between 18 and 35 years old with negative symptoms of at least moderate
severity, and who have been recently (< 2yrs) diagnosed with schizophrenia.
Intervention (if applicable): Individual and group-based CBT intervention targeting social
withdrawal.
Main study parameters/endpoints: Change in negative symptoms, Social functioning, and quality
of life, Productivity losses.
There is growing consensus that targeting negative symptoms such as social withdrawal is
essential to be able to preserve social participation; thereby reducing the high yearly costs
of schizophrenia.
Aaron T. Beck, founder of Cognitive Behavioural Therapy (CBT), and colleagues have developed
and investigated a new CBT approach, in which they target inactivity in a chronic
schizophrenia population with severe negative symptoms; a subgroup that has always believed
to be highly treatment resistant. The therapy is based on accumulating evidence that
dysfunctional beliefs in conjunction with neurocognitive impairments can impede functioning.
Its primary focus is to help patients overcome isolation and inactivity, thereby improve
quality of life, rather than primarily focussing on the reduction of psychotic symptoms.
Grant, Beck and colleagues found that patients treated with CBT not only showed more
improvement in global functioning than patients in the Standard Treatment condition, they
also showed a greater reduction in avolition/apathy and psychotic symptoms. These results
suggest that CBT can be highly successful in establishing clinically meaningful improvements.
Thus far, this intervention had only been investigated in patients with chronic schizophrenia
although there is increasing evidence that social withdrawal is also prominent in the early
phase of the illness. Moreover, there is growing consensus that early intervention is more
effective in improving illness course than intervention at a later stage of the illness.
In the present study the investigators aimed to examine whether a relatively short, partly
group based CBT targeting negative symptoms in recent-onset schizophrenia patients results in
reduced social withdrawal, need for care and improvement in quality of life and in overall
functioning compared to treatment as usual.
Primary Objective:
The primary aim of this project was to examine a shortened (+/- 20 sessions) and partly
group-based version of the new and promising CBT approach tested in a chronic population
(from now: 'Cognitive Behavioural Therapy - Social Activation' (CBTsa)), for its
applicability and effectiveness in a recent-onset population. The CBTsa has been adjusted to
the specific needs of the young recent-onset cohort.
Secondary Objective(s):
A secondary aim was explore the cost-effectiveness of this new intervention (i.e. the balance
between costs and health outcomes for CBTsa compared with treatment as usual(ST).
Hypotheses:
1. CBT focused on social activation (CBTsa) will result in a substantial reduction in
severity of negative symptoms, and in particular social withdrawal
2. The intervention will result in a reduction in need for care and QALY gain as a
consequence of improvement in symptoms and social functioning.
3. CBTsa will lead to an improvement in terms of Quality of Life and overall functioning
and symptomatology.
Study Design The present study entails a single-blind two-level RCT directed at patients with
recent onset schizophrenia. Participants will be randomly assigned to intervention condition
(Cognitive Behavioral Therapy- Social Activation (CBTsa) plus Standard Treatment (ST)), or to
the control condition (ST alone). Patients will be stratified by sex, as females with recent
onset schizophrenia have a better prognosis and may respond differentially to CBTsa. A
baseline test battery will be employed to examine causes of social withdrawal and interaction
with treatment outcome. Follow-up assessments (repetition test battery) will take place
directly after the intervention period and 6 months post-treatment.
Study population/ datasources Study sample: patients hospitalized or attending day-treatment
or receiving outpatient care at one of the participating centers. To maximize engagement,
group therapy will be incorporated in the day program. Individual therapy sessions will be
delivered flexibly (time, location). All participants are embedded within a low-threshold
intensive outreaching care system (aligned with our academic department).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00226278 -
Safety Study of ORG 34517 for Major Depression With Psychotic Features
|
Phase 2 |